| Assessment Status | Assessment Process Complete |
| HTA ID | 19010 |
| Drug | Risankizumab |
| Brand | Skyrizi® |
| Indication | Is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 04/03/2019 |
| Rapid review completed | 22/05/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/08/2019 |
| Pre-submission consultation with Applicant | 21/07/2020 |
| Full submission received from Applicant | 12/10/2020 |
| Preliminary review sent to Applicant | 09/03/2021 |
| NCPE assessment re-commenced | 15/04/2021 |
| Factual accuracy sent to Applicant | 16/07/2021 |
| NCPE assessment re-commenced | 26/07/2021 |
| NCPE assessment completed | 12/08/2021 |
| NCPE assessment outcome | The NCPE recommends that risankizumab (Skyrizi®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
The HSE has approved reimbursement following confidential price negotiations March 2022.
